Log in

Relevant bibliographies by topics / Squamous cell lung cancer, prognosis, NGS, RICTOR / Journal articles

To see the other types of publications on this topic, follow the link: Squamous cell lung cancer, prognosis, NGS, RICTOR.

Journal articles on the topic 'Squamous cell lung cancer, prognosis, NGS, RICTOR'

Author: Grafiati

Published: 11 March 2023

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 21 journal articles for your research on the topic 'Squamous cell lung cancer, prognosis, NGS, RICTOR.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Cheng, Haiying, Ni Fan, Ethan Sokol, et al. "RICTOR amplification as a novel therapeutic target for lung cancer brain metastases." Journal of Clinical Oncology 38, no. 15_suppl (2020): 3597. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.3597.

Full text

Abstract:

3597 Background: Approximately 20% to 50% of patients with advanced lung cancer develop brain metastases, which are associated with debilitating neurologic impairment and a dismal prognosis. There have been very limited studies investigating the genomics of brain metastases in lung cancer. Methods: We comprehensively investigated the frequency of PI3K/AKT/RICTOR/mTOR pathway aberrations in primary and metastatic sites using an extensive database of 11845 cases of lung adenocarcinoma by NGS (FoundationOne). The potential roles of RICTOR amplification in the development of brain metastases were

APA, Harvard, Vancouver, ISO, and other styles

2

Goffinet, Samantha, Veronique Hofman, Christophe Bontoux, et al. "EGFR assessment using next generation sequencing as a reflex testing on surgically resected non-squamous non-small cell lung carcinoma." Journal of Clinical Oncology 41, no. 16_suppl (2023): 8539. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.8539.

Full text

Abstract:

8539 Background: EGFR status assessment is mandatory in early stage (IB-IIIA) non-squamous non-small cell lung carcinoma (NS-NSCLC), but whether NGS methods should be used as reflex testing for this evaluation in daily practice is controversial. However, co-occuring mutations, notably TP53 mutations, may have an impact on tumor behavior and prognosis, and so, on future adjuvant therapeutic strategies. Methods: EGFR mutations were assessed prospectively using NGS (Oncomine Precision Assay genes panel) in 720 NS-NSCLC surgically resected between January 2021 and September 2022 in a single instit

APA, Harvard, Vancouver, ISO, and other styles

3

Laktionov, K. K., K. A. Sarantseva, L. A. Nelyubina, S. V. Gamayunov, E. A. Kolesnikova, and M. G. Gordiev. "KRAS-mutated non-small cell lung cancer: new therapy strategies." Siberian journal of oncology 23, no. 2 (2024): 72–81. http://dx.doi.org/10.21294/1814-4861-2024-23-2-72-81.

Full text

Abstract:

Lung cancer remains one of the most dangerous and most common cancers, requiring constant improvement of diagnostic and treatment methods. The genetic heterogeneity of lung cancer forces us to search for new therapeutic targets in an attempt to achieve greater effectiveness for certain groups of patients. The purpose of the study was to update current knowledge about lung adenocarcinoma with a mutation in the KRAS gene, to consider new opportunities for personalized treatment of KRAS-mutated NSCLC and to form an image of a Russian patient who is potentially indicated for targeted therapy. Mate

APA, Harvard, Vancouver, ISO, and other styles

4

Kato, Terufumi, Shingo Matsumoto, Shigeki Umemura, et al. "Therapeutic and prognostic impacts of specific gene alterations for squamous cell lung cancer: A result of nationwide genome screening in Japan (LC-SCRUM-Japan)." Journal of Clinical Oncology 37, no. 15_suppl (2019): 9060. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.9060.

Full text

Abstract:

9060 Background: Various gene alterations occur during the development of squamous cell lung cancer (SqLC), but specific gene alterations for SqLC and their clinical significance remain unknown. Methods: In a nationwide genome screening project (LC-SCRUM-Japan), we have prospectively analyzed lung cancer patients for genetic alterations using a next-generation sequencing (NGS) system, Oncomine Comprehensive Assay, and have established a large-scale clinico-genomic database. Results: Since February 2013 to December 2018, a total of 6692 lung cancer patients (686 SqLCs, 5360 non-squamous non-sma

APA, Harvard, Vancouver, ISO, and other styles

5

Wu, Fang, Chunhong Hu, Sujuan Zhang, et al. "Concurrent EGFR wild-type tongue squamous cell carcinoma and EGFR-mutant lung adenocarcinoma and response to osimertinib." Journal of Clinical Oncology 41, no. 16_suppl (2023): e18074-e18074. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e18074.

Full text

Abstract:

e18074 Background: Epidermal growth factor receptor (EGFR) mutation is most commonly oncogenic driver in lung adenocarcinoma with 50% incidence in Asians.Osimertinib is the third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), which has been widely used in metastatic EGFR-mutant non-small cell lung cancer (NSCLC) and has significantly improved outcomes. At present, the treatment of HNSCC mainly relies on surgery or chemoradiotherapy. EGFR is overexpressed in more than 90% of head and neck squamous cell carcinoma (HNSCC). Targeted therapy for HNSCC is mainly mo

APA, Harvard, Vancouver, ISO, and other styles

6

Ohashi, Kadoaki, Shingo Matsumoto, Kiyotaka Yoh, et al. "Contribution to the development of precision medicine and clinical utility of nationwide lung cancer genomic screening in Japan (LC-SCRUM-Japan)." Journal of Clinical Oncology 35, no. 15_suppl (2017): e20659-e20659. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e20659.

Full text

Abstract:

e20659 Background: A nationwide lung cancer genomic screening project in Japan (LC-SCRUM-Japan) was established in 2013. The objective of this project is to contribute to the development of precision medicine through the genomic biomarker screening, leading to improvement of patient prognoses. Methods: Advanced non-squamous non-small cell lung cancer (non-sq NSCLC) without EGFR mutations were eligible for inclusion. The tumors were analyzed for ALK/ROS1/RET fusions using RT-PCR and FISH. Since March 2015, the samples were further subjected to a next-generation sequencing (NGS) system, Oncomine

APA, Harvard, Vancouver, ISO, and other styles

7

Charkiewicz, Radoslaw, Anetta Sulewska, Alicja Charkiewicz, et al. "miRNA-Seq Tissue Diagnostic Signature: A Novel Model for NSCLC Subtyping." International Journal of Molecular Sciences 24, no. 17 (2023): 13318. http://dx.doi.org/10.3390/ijms241713318.

Full text

Abstract:

Non-small cell lung cancer (NSCLC) encompasses distinct histopathological subtypes, namely adenocarcinoma (AC) and squamous cell lung carcinoma (SCC), which require precise differentiation for effective treatment strategies. In this study, we present a novel molecular diagnostic model that integrates tissue-specific expression profiles of microRNAs (miRNAs) obtained through next-generation sequencing (NGS) to discriminate between AC and SCC subtypes of NSCLC. This approach offers a more comprehensive and precise molecular characterization compared to conventional methods such as histopathology

APA, Harvard, Vancouver, ISO, and other styles

8

Wang, Hongbiao, Yingcheng Lin, Jun Liu, Yuyin Cai, Xiaofang Qi, and Lujia Huang. "Abstract 5742: The landscape of genetic alteration in Chinese lung adenosquamous carcinoma patients." Cancer Research 82, no. 12_Supplement (2022): 5742. http://dx.doi.org/10.1158/1538-7445.am2022-5742.

Full text

Abstract:

Abstract Background: Lung adenosquamous carcinoma (LASC) is a mixed histologic component tumor type that contains both squamous cell carcinoma and adenocarcinoma, with each component accounting for at least 10% of tumors. The incidence of LASC is very low, only comprising 0.4-4% of all lung cancers. LASC yields a more aggressive clinical course, and its prognosis is generally worse than that of adenocarcinoma and squamous cell carcinoma of the lung. Due to the rarity of LASC, currently, there is no standard treatment. Also, to date, limited genomic data have been performed. In this study, we a

APA, Harvard, Vancouver, ISO, and other styles

9

Pai, Tanmayi, Marte Wasserman, Jason Lewis, et al. "Abstract PO2-20-08: Metastatic Lung Cancer Masquerading as Metaplastic Breast Cancer." Cancer Research 84, no. 9_Supplement (2024): PO2–20–08—PO2–20–08. http://dx.doi.org/10.1158/1538-7445.sabcs23-po2-20-08.

Full text

Abstract:

Abstract Background Metaplastic breast carcinoma (MBC) is an unusual malignancy that presents a diagnostic challenge due to the presence of varying cytomorphologies that can be seen in benign and malignant tumors. We posit that metastatic disease to the breast, itself an uncommon entity, should be considered in the differential diagnosis of MBC. We report a unique case of metastatic non-small cell lung cancer (NSCLC) with an actionable driver mutation that presented as a symptomatic breast mass and was initially considered to represent MBC. Report A 74-year-old woman with a 22-pack-year smokin

APA, Harvard, Vancouver, ISO, and other styles

10

John, Felix, Lea Ruge, Heather Scharpenseel, et al. "Molecular and clinical characteristics of patients with non-small-cell lung cancer (NSCLC) harboring KRAS G12V mutations." Journal of Clinical Oncology 42, no. 16_suppl (2024): 8618. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.8618.

Full text

Abstract:

8618 Background: KRAS G12V is one of the most common drivers of non-small cell lung cancer (NSCLC), accounting for around 3 percent of cases. Recently, there have been promising approaches in early clinical research to therapeutically target this mutation. However, this subset of patients is poorly characterized both molecularly and clinically, and data on therapy-dependent outcome are lacking. We performed this real world analysis to gain insight into the genomic and clinical characteristics of a large cohort of NSCLC patients with KRAS G12V mutations. Methods: Molecular data of 662 UICC stag

APA, Harvard, Vancouver, ISO, and other styles

11

Repetto, Matteo, Klaus Wagner, Shalabh Suman, et al. "Abstract 3365: Reliable detection of potentially therapeutically actionable ecDNA using clinical-grade NGS in a large pan-cancer cohort." Cancer Research 84, no. 6_Supplement (2024): 3365. http://dx.doi.org/10.1158/1538-7445.am2024-3365.

Full text

Abstract:

Abstract Background Focal high-level oncogene amplifications (FH-amp) (e.g., MYC, EGFR) frequently occur on extrachromosomal DNA (ecDNA), highly transcribed units of circular non-chromosomal DNA. FH-amp on ecDNA promote intra-tumoral heterogeneity, resistance to therapies, and poor prognosis. Recently, a Phase 1 clinical trial exploring ecDNA-directed treatments has begun. However, to date, bioinformatic detection of ecDNA has relied on whole-genome sequencing data, and no standard method exists to detect ecDNA on targeted NGS. We thus sought to explore the feasibility of detecting ecDNA in a

APA, Harvard, Vancouver, ISO, and other styles

12

Yu, Jieli, Minghui Wang, RongFeng Song, et al. "The landscape of chromosome 11q13 amplification in Chinese solid tumor patients and hyperprogressive disease (HPD) clinical example." Journal of Clinical Oncology 38, no. 15_suppl (2020): e15222-e15222. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e15222.

Full text

Abstract:

e15222 Background: Multiple biomarkers are thought to be effective guides in selecting immune checkpoint inhibitors, such as Tumor mutational burden (TMB), PD-L1 and MSI/dMMR. Immunotherapy may be miraculous effective in some patients but many other patients experienced poor prognosis and even tumor overgrowth after immunotherapy in real practice. Previous studies have reported that 11q13 (CCND1, FGF3, FGF4, and FGF19) amplifications were associated with HPD. However, the characterization of chromosome 11q13 amplification in Chinese solid tumor patients are not clear. Methods: A total of 10167

APA, Harvard, Vancouver, ISO, and other styles

13

Cui, Yanzhi, Da Jiang, Ran Hou, et al. "The clinicopathological characteristics, gene mutation characteristics and survival analysis of carcinoma of unknown primary origin." Journal of Clinical Oncology 39, no. 15_suppl (2021): e15098-e15098. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e15098.

Full text

Abstract:

e15098 Background: Analyze the characteristics of CUPS clinicopathology and gene mutation spectrum, and discuss CUPS drug treatment strategies. Methods: A retrospective analysis of the data of 30 patients with metastatic cancer of CUP admitted to our department from April 2015 to April 2020. Including clinicopathological characteristics, treatment process and methods, gene molecular information, follow-up survival period. The follow-up was until February 1, 2021 or the patient died. Results: The pathological types of these cases were adenocarcinoma (14/30,46.7%), squamous cell carcinoma (5/30,

APA, Harvard, Vancouver, ISO, and other styles

14

Qian, Jie, Rongrong Chen, Ruiying Zhao, Yuchen Han, and Yongfeng Yu. "Comprehensive Molecular Characterizations of Chinese Patients With Different Subtypes of Lung Squamous Cell Carcinoma." Frontiers in Oncology 10 (December 10, 2020). http://dx.doi.org/10.3389/fonc.2020.607130.

Full text

Abstract:

BackgroundThis study aims to profile integrative genomic spectra of Chinese patients with different subtypes of lung squamous cell carcinoma (LUSC) and explore potential molecular prognosis factors.MethodsWe retrospectively identified 204 surgically resected LUSC patients in Shanghai Chest Hospital who underwent capture-based targeted next-generation sequencing (NGS) with a panel of 68 lung cancer‐related genes from September 2017 to January 2019. NGS was used to profile comprehensive molecular characterizations.ResultsOf 204 cases, 114 (55.9%) were keratinizing squamous cell carcinoma (KSCC),

APA, Harvard, Vancouver, ISO, and other styles

15

Jin, Rui, Ling Peng, Jiawei Shou, et al. "EGFR-Mutated Squamous Cell Lung Cancer and Its Association With Outcomes." Frontiers in Oncology 11 (June 14, 2021). http://dx.doi.org/10.3389/fonc.2021.680804.

Full text

Abstract:

BackgroundThe therapeutic efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in advanced EGFR-mutant lung squamous cell carcinoma (SCC) patients remains uncertain. Furthermore, the factors underlying the responsiveness have not been fully investigated. We therefore investigated the link between genomic profiles and EGFR-TKI efficacy.Material and MethodsWe consecutively enrolled stage IV, EGFR-mutant, and EGFR-TKI–treated patients with SCC. Patients with EGFR wild-type lung SCC and EGFR-mutant lung adenocarcinoma were consecutively enrolled as controls, and next

APA, Harvard, Vancouver, ISO, and other styles

16

R. Teixeira, Manuel, Júlio Oliveira, Paula Borralho, et al. "Portuguese Consensus Recommendations for Next-Generation Sequencing of Lung Cancer, Rare Tumors, and Cancers of Unknown Primary Origin in Clinical Practice." Acta Médica Portuguesa 35, no. 13 (2022). http://dx.doi.org/10.20344/amp.17680.

Full text

Abstract:

Next-generation sequencing (NGS) has been implemented in clinical oncology for diagnosis, prognosis, and therapeutic guidance. Among the various NGS applications in molecular oncology, we focused on the following topics: laboratory standards for targeted gene panels (somatic mutations) and therapeutic guidance based on NGS of lung cancer and rare cancers, namely sarcomas and cancers of unknown primary. Multiple quality control checkpoints should be addressed in the pre-analytical phase for good quality and interpretation of the NGS results. It includes tumor size and cellularity, tissue proces

APA, Harvard, Vancouver, ISO, and other styles

17

Peng, Duanyang, Pingan Liang, Congying Zhong, et al. "Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non–small-cell lung cancer patients: a prospective observational study." BMC Cancer 22, no. 1 (2022). http://dx.doi.org/10.1186/s12885-022-10390-0.

Full text

Abstract:

Abstract Background Epidermal growth factor receptor (EGFR) amplification refers to the copy number increase of EGFR gene, and is often identified as a “bypass” way of Epidermal growth factor receptor Tyrosine kinase inhibitors (EGFR-TKI) resistance. We aimed to explore the effect of EGFR amplification on EGFR mutation treatment-naive advanced non-squamous non-small cell lung cancer (NSCLC) patients. Methods We conducted a prospective observational study in single center, enrolling advanced non-squamous NSCLC patients receiving Tyrosine kinase inhibitors (TKIs) between March 3, 2019, and Febru

APA, Harvard, Vancouver, ISO, and other styles

18

Kroening, Gianna, Jia Luo, Mark G. Evans, et al. "Multiomic Characterization and Molecular Profiling of Nuclear Protein in Testis Carcinoma." JCO Precision Oncology, no. 8 (October 2024). http://dx.doi.org/10.1200/po.24.00334.

Full text

Abstract:

PURPOSE Nuclear protein in testis carcinoma (NC) is an underdiagnosed and aggressive squamous/poorly differentiated cancer characterized by rearrangement of the gene NUTM1 on chromosome 15q14. Co-occurring alternations have not been fully characterized. METHODS We analyzed the genomic and immune landscape of 54 cases of NC that underwent DNA- and RNA-based NGS sequencing (Caris). RESULTS While NC is driven by NUTM1 fusion oncoproteins, co-occurring DNA mutations in epigenetic or cell cycle pathways were observed in 26% of cases. There was no significant difference between the fusion partner of

APA, Harvard, Vancouver, ISO, and other styles

19

Cai, Jun, Huihui Jiang, Shuqing Li, et al. "The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue Versus Circulating Tumor DNA in Chinese Patients With Non-Small Cell Lung Cancer." Frontiers in Oncology 11 (February 22, 2022). http://dx.doi.org/10.3389/fonc.2021.751106.

Full text

Abstract:

BackgroundCirculating tumor DNA (ctDNA) sequence analysis shows great potential in the management of non-small cell lung cancer (NSCLC) and the prediction of drug sensitivity or resistance in many cancers. Here, we drew and compared the somatic mutational profile using ctDNA and tumor tissue sequence analysis in lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC), and assess its potential clinical value.MethodsIn this study, 221 tumor tissues and 174 plasma samples from NSCLC patients were analyzed by hybridization capture-based next-generation sequencing (NGS) panel including 95 can

APA, Harvard, Vancouver, ISO, and other styles

20

Khosla, Harshit, Sarah Shaker, Ogochukwu Juliet Ezeigwe, et al. "TP53 mutation as a prognostic factor in metastatic non-small cell lung cancer (NSCLC): A retrospective review." Journal of Clinical Oncology 43, no. 16_suppl (2025). https://doi.org/10.1200/jco.2025.43.16_suppl.e20506.

Full text

Abstract:

e20506 Background: TP53 is one of the most commonly mutated genes found in all cancers including NSCLC. We assessed prevalence of TP53 mutation in patients with metastatic NSCLC at our institution and correlated with clinical characteristics and prognosis. Methods: We analyzed next-generation sequencing (NGS) results of the metastatic NSCLC patients diagnosed at our institution for which complete clinical characteristics were available between 2008-2022. Patients were divided into those with TP53 mutations and wild types. Clinical characteristics, treatment history and outcomes were evaluated

APA, Harvard, Vancouver, ISO, and other styles

21

Mfumbilwa, Zakile A., Janneke A. Wilschut, Martijn J. H. G. Simons, et al. "Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands." Scientific Reports, February 9, 2023. https://doi.org/10.1038/s41598-023-29286-5.

Full text

Abstract:

Recent discoveries in molecular diagnostics and drug treatments have improved the treatment of patients with advanced (inoperable) non-squamous non-small cell lung cancer (NSCLC) from solely platinum-based chemotherapy to more personalized treatment, including targeted therapies and immunotherapies. However, these improvements come at considerable costs, highlighting the need to assess their cost-effectiveness in order to optimize lung cancer care. Traditionally, costeffectiveness models for the evaluation of new lung cancer treatments were based on the findings of the randomized control trial

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!